Desmopressin
Also known as: 1-deamino-8-D-arginine vasopressin, 1-desamino-8-D-arginine vasopressin, DDAVP, Minirin, Nocdurna, Stimate
Source Desmopressin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Desmopressin is a synthetic analogue of the antidiuretic hormone vasopressin. It is prescribed to reduce urine output in children with nocturnal enuresis, to provide a short‑term hemostatic boost in mild hemophilia or von Willebrand disease, and as a pharmacologic stimulus in dynamic testing to differentiate Cushing syndrome subtypes. The drug is approved for clinical use and is available in several formulations for intranasal, oral, subcutaneous, intravenous, and sublingual administration.
Mechanism of Action
Desmopressin acts primarily as an agonist at the V2 receptors of the renal collecting duct, promoting insertion of aquaporin‑2 water channels and enhancing water reabsorption, which concentrates urine. In endothelial cells, V2 activation triggers release of von Willebrand factor and factor VIII, improving primary hemostasis. The same V2‑mediated pathway also stimulates ACTH secretion from the pituitary, which underlies its use in the desmopressin stimulation test for Cushing syndrome evaluation.
What the Research Shows
Systematic reviews and meta‑analyses have quantified desmopressin’s performance across its indications. In the differential diagnosis of Cushing syndrome, the desmopressin stimulation test showed pooled sensitivity of 86% and specificity of 90% across 21 studies, comparable to dexamethasone‑CRH testing. For nocturnal enuresis, a 2025 review of pediatric studies reported that desmopressin, alone or combined with anticholinergics, yields superior efficacy and faster response than monotherapy, supporting its role as a first‑line pharmacologic option. An older anesthesiology review described desmopressin as a safe, effective hemostatic agent for mild‑to‑moderate hemophilia and von Willebrand disease, noting the need for a trial dose to confirm factor elevation before surgery. Evidence gaps remain regarding long‑term safety in children and the drug’s benefit in patients with normal hemostasis.
Reported Benefits
Desmopressin reduces nocturnal urine output, increasing the number of dry nights in children with enuresis and improving quality of life. In bleeding disorders, it raises circulating factor VIII and von Willebrand factor, providing a rapid, non‑blood product hemostatic option for minor surgeries. As a diagnostic stimulus, its high specificity (90%) helps clinicians distinguish Cushing disease from pseudo‑Cushing states, guiding appropriate treatment pathways.
Limitations of the Evidence
Response to desmopressin varies; patients with hemophilia or von Willebrand disease must undergo a test dose to verify factor rise, limiting its universal applicability. Diagnostic studies show moderate heterogeneity and risk of bias, and the test is less sensitive than dexamethasone‑CRH for Cushing syndrome. Evidence for use in individuals with normal hemostasis is limited, and long‑term safety data in pediatric enuresis are sparse. Data on interactions with aspirin or other antiplatelet agents are lacking.
Safety Considerations
Desmopressin is generally well tolerated, but hyponatraemia can occur, especially with intranasal or oral dosing in children or patients with excessive fluid intake. Monitoring of serum sodium is advised during initial therapy. While anecdotal concerns about thrombosis exist, controlled studies have not demonstrated a significant increase in thrombotic events. Patients with uncontrolled hypertension, severe renal impairment, or on concomitant antiplatelet therapy should be evaluated cautiously.
How It Is Administered
Desmopressin is formulated for intranasal spray, oral tablets or melt‑in‑mouth preparations, sublingual tablets, and injectable solutions for intravenous or subcutaneous use. The choice of route depends on the clinical indication—intranasal or oral for enuresis, injectable for peri‑operative hemostasis, and standardized dosing for diagnostic stimulation tests. Formulations are prescription‑only.
Routes of Administration
Goals & Uses
- Nocturia reduction in adultsUrologyHigh
- Hemostasis in mild hemophilia A / vWD type 1HematologyHigh
- Central diabetes insipidus managementEndocrine / RenalHigh
- Hemostatic agent in uremia-related platelet dysfunctionHematology / NephrologyModerate
- Nocturnal enuresisUrologyHigh
- Primary nocturnal enuresis treatmentUrology / PediatricsHigh
- Bleeding control in hemophilia A / vWDHemostasisHigh
- Central diabetes insipidusEndocrineHigh
- Cranial surgery/trauma-related polyuriaNeurosurgery / Critical CareModerate
Contraindications
- Syndrome of inappropriate antidiuretic hormone secretion (SIADH)EndocrineHigh
- Hyponatremia or risk of severe hyponatremiaElectrolyte DisorderHigh
- von Willebrand disease type 2BHematologyHigh
- Hyponatremia or history of hyponatremiaElectrolyte DisorderHigh
- Known hypersensitivity to desmopressinAllergyHigh
- Severe renal impairmentOrganModerateKidney function concerns
- Polydipsia (primary or psychogenic)Psychiatric / BehavioralHigh
- Hypersensitivity to desmopressinAllergy / ImmunologyHigh
- Moderate to severe renal impairment (CrCl <50 mL/min)RenalHigh
Adverse Effects
- HypertensionCardiovascularRareHigh blood pressure
- Injection site reactionsLocalUncommon
- HeadacheNeurologicCommonPain in the head or upper neck
- Flushing / Facial flushingDermatologicalUncommon
- Abdominal crampsGastrointestinalUncommon
- FlushingVascularCommonWarmth and redness of the skin
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- HyponatremiaElectrolyteCommon
- Nasal congestion / rhinitisENTCommon
Drug Interactions
- Selective serotonin reuptake inhibitors (SSRIs)Moderate
- Tricyclic antidepressantsModerate
- CarbamazepineModerate
- NSAIDsModerateMay increase renal risk in susceptible patients
- Lamotrigine / ValproateLow
- Thiazide diureticsHigh
Population Constraints
- PregnancyReproductive SafetyRelative
- Cardiovascular disease / hypertensionCardiovascularRelative
- ElderlyAgeRelative
- Children under 5 yearsPediatricRelative
- Pediatric patients (≤6 y)AgeRelative
- Cystic fibrosisPulmonary / GeneticRelative
- Elderly patients (≥65 years)Age RelatedRelative
- BreastfeedingReproductiveRelative
Regulatory Status
- European UnionApprovedApproved: central diabetes insipidus, nocturnal enuresis, bleeding disordersAvailable as Minirin.
- United StatesApprovedApproved: central diabetes insipidus, nocturnal enuresis, hemophilia A, von Willebrand diseasePrescription product (DDAVP).
- United KingdomApprovedApproved: central diabetes insipidus, nocturnal enuresis, bleeding disordersPrescription‑only medicine.
FDA‑approved in 1978 (DDAVP®). Approved in EU and UK for the same indications. Available as intranasal spray, oral tablets, and injectable forms.
Evidence & Sources
- Journal ArticleHighHinojosa-Amaya JM, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleHighCammisa I, Zona M, Ferrara P2025-01-01T00:00:00.000000Z
- Journal ArticleModerateHorrow JC1990-01-01T00:00:00.000000Z
- Journal ArticleModerateTsuji S, Kaneko K2023-01-01T00:00:00.000000Z
- Journal ArticleHighCeccato F, et al.2023-01-01T00:00:00.000000Z
Frequently Asked Questions
How quickly does desmopressin work for bedwetting?
Clinical reviews report that desmopressin can increase the number of dry nights within days to weeks, especially when combined with anticholinergic agents. Individual response varies, so clinicians often assess effectiveness after a short trial period.
Can desmopressin replace blood product transfusions in surgery?
In patients with mild‑to‑moderate hemophilia or von Willebrand disease, a trial dose of desmopressin can raise factor VIII and vWF enough to reduce or avoid transfusion for minor procedures. Confirmation of factor increase is required before relying on it.
Is desmopressin safe for children with normal kidney function?
The drug is generally safe, but the risk of hyponatraemia mandates monitoring of fluid intake and serum sodium, particularly in younger children or those receiving intranasal or oral forms.
Why is the desmopressin stimulation test used in Cushing syndrome evaluation?
Desmopressin stimulates ACTH release via V2 receptors, producing a cortisol response that helps differentiate true Cushing disease from pseudo‑Cushing states. Meta‑analysis shows the test has high specificity (≈90%) for this purpose.
What are the main side effects to watch for?
The most common adverse effect is dilutional hyponatraemia, which can present with headache, nausea, or seizures if severe. Mild flushing or nasal irritation may occur with intranasal use, and rare reports of thrombosis have not been confirmed in controlled studies.
What is Desmopressin?
Desmopressin is a synthetic analogue of the antidiuretic hormone vasopressin. It is prescribed to reduce urine output in children with nocturnal enuresis, to provide a short‑term hemostatic boost in mild hemophilia or von Willebrand disease, and as a pharmacologic stimulus in dynamic testing to differentiate Cushing syndrome subtypes. The drug is approved for clinical use and is available in several formulations for intranasal, oral, subcutaneous, intravenous, and sublingual administration.
What is Desmopressin used for?
Desmopressin is educationally associated with: Nocturia reduction in adults, Hemostasis in mild hemophilia A / vWD type 1, Central diabetes insipidus management, Hemostatic agent in uremia-related platelet dysfunction, Nocturnal enuresis, Primary nocturnal enuresis treatment, Bleeding control in hemophilia A / vWD, Central diabetes insipidus, Cranial surgery/trauma-related polyuria. Educational only — not medical advice.
How is Desmopressin administered?
Recorded routes of administration: Intranasal, Intravenous, Oral, Subcutaneous, Sublingual.
What are the potential side effects of Desmopressin?
Reported adverse effects include: Hypertension, Injection site reactions, Headache, Flushing / Facial flushing, Abdominal cramps, Flushing, Nausea, Hyponatremia, Nasal congestion / rhinitis. This list is not exhaustive — consult a qualified clinician.
Who should avoid Desmopressin?
Recorded contraindications: Syndrome of inappropriate antidiuretic hormone secretion (SIADH), Hyponatremia or risk of severe hyponatremia, von Willebrand disease type 2B, Hyponatremia or history of hyponatremia, Known hypersensitivity to desmopressin, Severe renal impairment, Polydipsia (primary or psychogenic), Hypersensitivity to desmopressin, Moderate to severe renal impairment (CrCl <50 mL/min). Consult a qualified clinician before use.